Cardiac Toxicities Following Chimeric Antigen T-cell Therapy: A Post-Marketing Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System
Key Points
Cardiac toxicities occur across various cases following chimeric antigen receptor therapy, indicating a significant safety issue.
From the FDA adverse event reporting system, over 500 instances of cardiac-related events were documented after T-cell therapy.
This observational analysis utilized data from the FDA adverse event reporting system to assess the risks associated with chimeric antigen receptor therapy.
These findings underscore the need for vigilance in monitoring patients for cardiac toxicities after immunotherapy interventions.
Like
Bookmark
Share
Like
Bookmark
Share
Cardiac Toxicities Following Chimeric Antigen T-cell Therapy: A Post-Marketing Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System | Synapse